News - Latest
108 news items
Request to take over the Fucidin marketing authorisation
The company Leo Pharma B.V. has informed the Medicines Evaluation Board (MEB) that the production of the antibiotic Fucidin ...
Request to take over the pyridoxine hydrochloride marketing authorisation
The company Pharmachemie B.V. has requested the Medicines Evaluation Board (MEB) to withdraw marketing authorisation for ...
Coronavirus - MEB employees work from home
Complying with the Dutch government guidelines regarding the coronavirus situation, MEB employees will be working from home as of ...
Regulatory Science Magazine 10: Reduction, replacement and refinement of animal studies
This week, the newest edition of the Regulatory Science Magazine was issued. This 10th edition of the online science magazine of ...
Amended policy on DHPCs
The Medicines Evaluation Board (MEB) has amended its policy on Direct Healthcare Professional Communications (DHPCs). This ...
Citrix systems back online
The MEB Citrix systems have been put back into use. The safety patches for the Citrix systems have been installed and operations ...
MEB Citrix systems switched off
Out of precaution the MEB Citrix systems have been switched off, due to the recent Citrix safety warnings. As a result, MEB ...
Shorter timetable for procedure for changing parallel package leaflet
The Medicines Evaluation Board (MEB) has decided to implement a shorter timetable for the procedure for changing the parallel ...
MEB fee rate change as of January 2020
The Medicines Evaluation Board (MEB) is increasing the fee rates for authorisation applications, authorisation changes and the ...
Regulatory Science Magazine 9: opioids and Real World Data
Today the Medicines Evaluation Board (MEB) publishes the 9th edition of its Regulatory Science Magazine. This edition features ...